Regulatory Story
Go to market news section View chart   Print

Annual Financial Report

Released 12:56 21-Sep-2018

RNS Number : 5814B
21 September 2018

For immediate release

21 September 2018


(the 'Company')


Publication of 2018 Annual Report and Accounts


Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that its Annual Report and Accounts for the year ended 30 June 2018 will be published today on the Company's investor relations website,


It will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications.  Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on the Company's investor relations website,




For further information please contact:

Abcam plc

+ 44 (0) 1223 696 000

Suzanne Smith, Company Secretary

James Staveley, Vice President Investor Relations


J.P.Morgan Cazenove - Nominated Advisor & Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Jonty Edwards

FTI Consulting

+ 44 (0) 20 3727 1000


About Abcam plc


As an innovator of reagents and tools, Abcam's purpose is to serve life scientists globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated biological binders and assays to address important targets in critical biological pathways.

A pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's antibodies and affinity binders, reagents, biomarkers and assays and the Group's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.


Abcam's eleven locations are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Group sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).


To discover more, please visit and 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Annual Financial Report - RNS